Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdomyosarcoma 1Neoplasms 1Myelodysplastic Syndromes 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Fanconi Anemia 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 168Radiotherapy 110pembrolizumab 96Cetuximab 95Docetaxel 74Carboplatin 74Radiotherapy, Intensity-Modulated 55Paclitaxel 51Nivolumab 50Fluorouracil 47Surgical Procedures, Operative 28Radiation 26Magnetic Resonance Spectroscopy 25durvalumab 23Drug Therapy 23Radiosurgery 21Biopsy 19Albumin-Bound Paclitaxel 19130-nm albumin-bound paclitaxel 18Taxes 17tislelizumab 16toripalimab 15Chemoradiotherapy 15Neoadjuvant Therapy 14Erlotinib Hydrochloride 14Blood Specimen Collection 14camrelizumab 13Immunohistochemistry 13Specimen Handling 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Squamous Cell Carcinoma of Head and Neck × prexasertib × Clear all
NCT06597565 2025-10-20

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
43 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡